Board Member
Xilio Therapeutics, Inc. (XLO)Board Member
Anika Therapeutics, Inc. (ANIK)Equibles does not estimate personal net worth.
Get an email with a short summary when Anika Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ANIK alertsCheryl Blanchard is recorded as Board Member at Anika Therapeutics, Inc. (ANIK) since January 1, 2018, CEO at Anika Therapeutics, Inc. (ANIK) and Board Member at Xilio Therapeutics, Inc. (XLO). The newest filing on record that lists Cheryl Blanchard as Board Member at Xilio Therapeutics, Inc. (XLO) is dated April 28, 2026. The proxy statement of Anika Therapeutics, Inc. reports total compensation of $4,887,318 for Cheryl Blanchard in fiscal 2025, including a base salary of $750,397. Disclosed compensation is on record for 8 fiscal years. Cheryl Blanchard has spoken on 23 earnings calls across 1 company, most recently for Anika Therapeutics, Inc. on November 5, 2025. Anika Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Xilio Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Anika Therapeutics, Inc. includes Stephen (Steve) Griffin (CEO and Board Member), Stephen D. Griffin (CEO, CFO and Board Member), Steve Griffin (CEO and Board Member) and 7 others.
“Good morning, everyone, and thanks for joining us today to discuss Anika's third quarter 2025 results. Please turn to Slide 3.”
“Good morning, everyone, and thank you for joining us today to discuss Anika's second quarter 2025 results. Please turn to Slide 3. This has been a meaningful quarter for Anika, including a significant clinical update on Hyalofast.”
“On balance, we've had a successful start to the year as we had continued strong performance in our commercial channel and advanced many of our key goals and objectives.”
“I'm pleased to report that since our last call we've made meaningful progress advancing our strategic initiatives and refocusing our strategy. As we've communicated, a key objective has been to focus our human and financial capital on our most promising opportunities to create shareholder value.”
“Today marks an important day in the Anika story, and I'll start by providing an update on our ongoing strategic review that has been focused on driving the most optimal capital allocation structure.”
2018-01-01–present
Proxy statement
Start not stated–present
Last confirmed April 28, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2018-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Anika Therapeutics, Inc. (ANIK) | CEO | $750,397 | $4,887,318 |
| 2024 | Anika Therapeutics, Inc. (ANIK) | CEO | $743,943 | $5,103,466 |
| 2023 | Anika Therapeutics, Inc. (ANIK) | CEO | $726,000 | $4,459,800 |
| 2022 | Anika Therapeutics, Inc. (ANIK) | CEO | $695,100 | $5,940,722 |
| 2021 | Anika Therapeutics, Inc. (ANIK) | CEO | $668,400 | $4,202,608 |
| 2020 | Anika Therapeutics, Inc. (ANIK) | CEO | $548,077 | $10,029,434 |
| 2019 | Anika Therapeutics, Inc. (ANIK) | CEO | — | — |
| 2018 | Anika Therapeutics, Inc. (ANIK) | CEO | — | — |
